Insomnia is a specific sleep disorder characterised by persistent difficulty initiating or maintaining sleep, or non-restorative sleep, causing significant daytime impairment. It is distinct from the broader category of sleep disorders, which encompasses a wider range of sleep-related conditions. This distinction matters clinically: medical cannabis for insomnia is considered only after established first-line treatments have been tried and found inadequate.

First-Line Treatments: NICE and CBT-I

NICE Guideline CG133 (Insomnia) identifies cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia in adults. CBT-I addresses the thoughts, behaviours, and environmental factors that perpetuate insomnia, and it has the strongest long-term evidence base of any insomnia treatment. Sleep restriction therapy, stimulus control, and relaxation techniques are all components of CBT-I. Access is available via the NHS Talking Therapies programme in many areas, and digital CBT-I programmes are also available.

Where pharmacological treatment is used, NICE guidance recommends using the lowest effective dose for the shortest possible duration. Hypnotic medications — including z-drugs such as zopiclone and temazepam — carry risks of tolerance, dependence, and morning sedation. They are not intended for long-term use. Medical cannabis is not a first-line option. It is considered where CBT-I has been attempted, where hypnotics have been inadequate or inappropriate, and where the insomnia is either a primary condition causing significant functional impairment or is comorbid with another qualifying condition.

Insomnia vs Sleep Disorders: The Clinical Distinction

The distinction between insomnia as a specific diagnosis and the broader category of sleep disorders is important for the prescribing pathway. Insomnia disorder — as defined by DSM-5 and ICD-11 — requires at least three months of sleep difficulties occurring at least three nights per week, despite adequate sleep opportunity, causing clinically significant distress or functional impairment. Many patients presenting for medical cannabis assessment for sleep problems will have insomnia disorder as the primary diagnosis. Others will have insomnia as a symptom of another condition — anxiety, chronic pain, PTSD, or fibromyalgia — in which case the comorbid condition may provide the primary prescribing indication.

The Endocannabinoid System and Sleep Architecture

CB1 receptors are expressed throughout the brain regions involved in sleep-wake regulation, including the hypothalamus, basal ganglia, brainstem, and limbic system. The endocannabinoid system plays a modulatory role in sleep homeostasis, and endogenous cannabinoids including anandamide and 2-AG fluctuate across the sleep-wake cycle. Disruption of the endocannabinoid system has been associated with sleep abnormalities in preclinical and early clinical research.

THC has sedative properties at low doses, primarily mediated via CB1 receptor agonism. It reduces sleep onset latency and can increase total sleep time. However, THC also suppresses REM sleep, and the clinical significance of this effect over the long term remains an area of ongoing research. Chronic THC use may also reduce slow-wave sleep and lead to tolerance to its sedative effects. CBD has a more complex relationship with sleep: at lower doses it may have alerting properties, while at higher doses it may support sleep, possibly via anxiolytic mechanisms rather than direct sedation. The anxiolytic effect of CBD is relevant for patients whose insomnia is driven by anxiety, hyperarousal, or ruminative thinking at bedtime.

Evidence Base for Medical Cannabis in Insomnia

The evidence for cannabis-based medicines specifically in insomnia disorder is moderate. There are no large, double-blind randomised controlled trials with cannabis-based medicines focused exclusively on primary insomnia. However, observational data from clinic populations and smaller clinical studies show consistent improvements in subjective sleep quality, sleep onset, and total sleep time, particularly with balanced THC:CBD formulations. Real-world evidence from Canadian and Australian medical cannabis programmes has demonstrated meaningful improvements in patient-reported sleep outcomes.

There is no NICE guideline that directly addresses cannabis-based medicines for insomnia. However, NICE does acknowledge that unlicensed cannabis-based medicines can be prescribed by GMC-registered specialists where there is a clinical need and where other treatments have been inadequate. Insomnia that is comorbid with another condition — such as chronic pain, anxiety, or PTSD — is more commonly the clinical basis for prescribing than insomnia as a standalone primary diagnosis.

Who Qualifies for a Medical Cannabis Prescription for Insomnia

To be considered for a medical cannabis prescription for insomnia in the UK, patients are typically expected to demonstrate: a diagnosis of chronic insomnia disorder (at least three months, occurring at least three nights per week); documented attempts at first-line treatment, specifically CBT-I or structured sleep hygiene programmes; a trial of pharmacological treatment where clinically appropriate (zopiclone, temazepam, or other hypnotics), with inadequate response, adverse effects, or contraindication; and significant functional impairment attributable to the insomnia. Where insomnia is comorbid with another condition — anxiety, PTSD, chronic pain — the assessment will consider the full clinical picture.

UK Prescribing Practice

Private cannabis clinics in the UK that prescribe for sleep-related conditions typically offer specialist consultations with psychiatrists, neurologists, or general practitioners with specialist interest in cannabis medicine. A GP referral is not required. Patients are asked to bring records of their diagnosis and treatment history, including documentation of CBT-I participation or referral, and any pharmacological treatments trialled. Formulations typically prescribed for insomnia include CBD-dominant oils for patients where anxiety is the dominant driver, and balanced THC:CBD or THC-dominant oils (in low doses) for patients with significant sleep onset difficulty. See UK medical cannabis clinics and how to get a medical cannabis prescription in the UK.

Frequently Asked Questions

Is insomnia an approved indication for medical cannabis in the UK?

There is no formal approved-indication list for cannabis-based medicines in the UK. A GMC-registered specialist can prescribe cannabis-based medicines for insomnia under the unlicensed framework where first-line treatments including CBT-I have been tried and found inadequate, and where the clinical picture supports it. Comorbid conditions such as chronic pain, anxiety, or PTSD often strengthen the clinical case.

Do I need to have tried sleeping tablets before I can be prescribed medical cannabis for insomnia?

Not necessarily, but demonstrating a reasonable treatment history is important. Most specialists will want to see that sleep hygiene, CBT-I, and where appropriate pharmacological options have been considered. If hypnotics are contraindicated or have caused problematic side effects, that is clinically relevant.

Will medical cannabis improve my sleep long-term?

The evidence suggests that cannabis-based medicines can improve subjective sleep quality, reduce sleep onset latency, and increase total sleep time in many patients. However, tolerance to the sedative effects of THC can develop over time, and some patients require dose adjustments. Specialist follow-up is important to monitor response and manage any tolerance effects.

What is the difference between CBD oil from a health shop and a prescribed cannabis medicine for insomnia?

Over-the-counter CBD products sold as food supplements in the UK are not regulated as medicines and are limited to very low doses. Prescribed cannabis-based medicines are manufactured to pharmaceutical standards, contain verified cannabinoid content, and may include THC. Prescribed medicines are dispensed by licensed pharmacies and monitored by a specialist throughout treatment.

Can insomnia be treated with medical cannabis if it is caused by another condition?

Yes — and in many cases, where insomnia is a significant symptom of a qualifying comorbid condition such as chronic pain, PTSD, anxiety, or fibromyalgia, the clinical case for prescribing is often stronger. The specialist will assess the full clinical picture. Both the insomnia and the underlying condition should be clearly documented when presenting for assessment.